U.S. Markets open in 6 hrs 33 mins

Why Investors Should Favor Smaller Biotech Companies

Alexander Nicoll

Large biotech companies are cashing in on small and mid-cap firms and investors should follow suit, experts say. Smaller biotech firms have hit huge paydays in 2018 as larger companies continue to add these firms' drugs to their own pipelines, expanding their clinical assets. Global acquisitions of biotech companies are expected to be at the highest annual level in 12 years, according to Bloomberg data.